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Guidelines and Guidance
I
n December 1995, results from the National Institute 
for Neurological Disorders (NINDS) Recombinant 
Tissue Plasminogen Activator (rt-PA) Stroke Trial were 
published [1]. The implications of this trial have been 
profound, affecting the emergency management of stroke 
patients as well as any patient with apparent symptoms of an 
ischemic stroke. 
Based on the NINDS ﬁ  ndings, the United States Food 
and Drug Administration approved the use of rt-PA for 
the treatment of acute ischemic stroke. Subsequent to this 
approval, both the American Heart Association and the 
American Academy of Neurology endorsed the use of rt-PA 
for selected stroke patients [2,3]. 
The approval and endorsement of rt-PA for stroke therapy 
has been controversial. Since the publication of the NINDS 
rt-PA trial, concerns regarding the study’s design, results, 
and ramiﬁ  cations have been published and disseminated. 
Speciﬁ  c criticisms of the NINDS trial have included: (1) lack 
of early improvement (within 24 hours) in patients treated 
with rt-PA; (2) a trial enrollment policy that required half 
of the participants to be treated within 0–90 minutes of 
presentation and the remainder at 91–180 minutes—thereby 
not reﬂ  ecting a “real world” setting; (3) discrepancies in 
baseline characteristics of patients favoring those treated with 
rt-PA; (4) a small sample size with resulting large conﬁ  dence 
intervals; and (5) a reported beneﬁ  t of therapy, a ﬁ  nding 
inconsistent with previous thrombolytic trials in stroke [4–8]. 
Additional concerns have been expressed regarding 
the generalization of the NINDS results to the community 
hospital setting, the reorientation of emergency medical 
systems, and an unacceptably high risk of harm with limited 
beneﬁ  t to patients. The NINDS authors have attempted to 
address many of these concerns [9], and supporters have 
defended and encouraged the increased use of rt-PA in 
patients with acute stroke [10,11]. 
In hopes of clarifying many of the issues raised, researchers 
who were not involved in the NINDS study have made 
requests for access to the NINDS rt-PA trial data. Access to 
this data was initially denied, even after petition to the Food 
and Drug Administration under the Freedom of Information 
Act, heightening concern and suspicions regarding the 
trial ﬁ  ndings [12]. During this period, the NINDS authors 
published no less than 27 reports using various permutations 
of the NINDS dataset [9,13–38]. 
In October 2003, nearly eight years after the NINDS 
publication, the original data from the NINDS rt-PA Stroke 
Trial were made available to the public. Since this time, we 
are aware of only three reports by non-NINDS researchers 
that have used the original dataset [39–41].
We document our efforts to access and decipher the 
NINDS rt-PA Stroke Trial dataset. By documenting the 
steps necessary to obtain and organize the data, along with 
a description of each data point, we hope to assist future 
researchers and clinicians who desire to further analyze this 
landmark trial. 
Obtaining the NINDS rt-PA Database
A CD-ROM containing the NINDS rt-PA database can be 
purchased from the National Technical Information Service 
(http://www.ntis.gov/; 1-888-584-8332). The cost is US$79.00 
plus US$5.00 for shipping and handling, and delivery can 
be expected within seven to ten business days. However, the 
data on the CD-ROM are not in a readable format. Multiple 
conversions are required, which can only be accomplished 
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Summary Points
•  In 1995, the NINDS rt-PA study documented an improvement 
in neurologic outcomes at three months for those patients 
given rt-PA within 3 hours of onset of an acute ischemic 
stroke.
•  This trial has become the sentinel study supporting the use of 
rt-PA in acute ischemic stroke.
•  Questions raised regarding this trial have been difﬁ  cult to 
answer, since the raw data have been unavailable to non-
NINDS researchers.
•  In October 2003, the data from this trial became available for 
purchase.
•  In this report, we describe the process of acquiring and 
deciphering the dataset from the original trial, provide 
a detailed description of the dataset, and discuss the 
implications for potential future research.PLoS Medicine  |  www.plosmedicine.org 0706 May 2008  |  Volume 5  |  Issue 5  |  e113
with technical assistance from the software company (SAS 
Institute,; http://www.sas.com/). Once these conversions are 
completed and the data are placed in an Excel spreadsheet 
format, no key accompanies the dataset to decode the 
numeric designations given to the variables.
The steps necessary to obtain the NINDS database, software 
requirements, necessary conversions, additional instructions, 
incomplete/missing data, and methods used to decode data 
variables are documented in Text S1. 
Patient Results in the Database
There are 100 separate variables recorded for the 624 patients 
enrolled in the NINDS study. Text S2 documents each 
individual variable in the order in which it is displayed in the 
Excel format.
Patient results can be divided into nine natural 
groupings: A, baseline characteristics; B, patient 
demographics; C, baseline vital signs and laboratory values; 
D, head computerized tomography results; E, treatment 
randomization and timing of drug delivery; F, deleterious 
effects (death and hemorrhage); G, neurological outcomes; 
H, dosing of rt-PA and use of heparin; and I, stroke type and 
clinical outcomes. Text S3 summarizes the data for each of 
the above groups and details the location of missing data, 
inconsistencies with previous reported data, and protocol 
violations not previously reported. Texts S4 through S12 
present the results of every variable in the groups noted 
above. 
Discussion 
This report is intended to demonstrate the process for 
establishing access and analyzing the NINDS rt-PA Stroke 
Trial dataset. While the purchase of the database is simple, 
the process of gaining access to the information on the 
CD-ROM is convoluted and difﬁ  cult. We have summarized 
these steps and provided access to the entire database for 
researchers desiring to analyze the data from this landmark 
trial for independent research queries.
Some may suggest that a reanalysis of the NINDS rt-PA 
database is not necessary and that those who review the data 
are immersed in a futile attempt to topple or tarnish the 
study’s impact. However, the NINDS rt-PA trial has guided 
the worldwide care of acute ischemic stroke victims since its 
publication. The study has been referenced over 1,900 times 
[42] and stands alone as the largest randomized control trial 
to demonstrate rt-PA’s beneﬁ  t in patients with acute ischemic 
stroke. 
The data from this trial have been incorporated into 
inﬂ  uential pooled analyses [31] and reviews [43], with 
the salutary results widely promoted by groups such as the 
American Heart Association and American Stroke Association 
as the basis of the “Brain Attack” campaign and the creation 
of stroke centers. Until the results of future prospective 
trials such as IST-3 (The Third International Stroke Trial), 
ECASS-3 (The European Cooperative Acute Stroke Study), 
and EPITHET (Echoplanar Imaging Thrombolysis Evaluation 
Trial) become available, the NINDS rt-PA study will likely 
continue to provide the primary evidence for the use of 
thrombolytic therapy in the management of acute ischemic 
stroke. 
Accessing the database as described in this report can lead 
to future investigation by interested researchers. There have 
been few studies by non-NINDS researchers using the original 
NINDS data. Published reports include: (1) an analysis of 
potential baseline imbalances in the NINDS trial, and (2) a 
review of severity-adjusted end points [39,40]. Both of these 
studies support the use of rt-PA in acute ischemic stroke. In 
a more recent reanalysis of the NINDS data, Hoffman and 
Schriger found similar responses to treatment in the placebo 
and rt-PA treatment groups [41]. Contradictory opinions 
and analyses of the original NINDS data such as these have 
fueled the controversy regarding the risks and beneﬁ  ts of 
rt-PA therapy in acute ischemic stroke. Our report provides 
researchers with a method to easily access the NINDS 
database for independent analysis in the hope that further 
review of this investigation will yield future insights into the 
risks and/or beneﬁ  ts of this intervention.
Analysis of patients in this trial with elevated blood pressure 
[15], elevated glucose levels [16], transient ischemic attacks 
[26], and minor strokes [36] have been performed by the 
NINDS researchers. Other subgroups of patients, such as 
those who received aspirin, those with congestive heart 
failure, those with prior strokes, and many others can now be 
analyzed, with the understanding that such subgroup analysis 
should not guide therapeutic decisions but may allow the 
creation of new hypotheses for future studies. 
While the purchased dataset provides a large amount of 
data, some data appear to be missing. Documentation of 
inclusion and exclusion criteria in the dataset is incomplete 
Box 1. Inclusion and Exclusion Criteria
Measurements Available in Dataset
•  Onset of ischemic stroke symptoms
• Deﬁ  cit measurable on the National Institutes of Health Stroke 
Scale 
•  Baseline computerized tomography scan of the brain showing 
no intracranial hemorrhage
•  Systolic blood pressure above 185 mm Hg or diastolic blood 
pressure above 110 mm Hg
•  Patients taking heparin within 48 hours
•  Glucose concentration <50 mg per deciliter or >400 mg per 
deciliter
Measurements Not Available in Dataset
•  History of stroke or serious head trauma in the preceding 
three months
•  Major surgery in the past 14 days
•  History of intracranial hemorrhage
•  Rapidly improving or minor symptoms
•  Symptoms suggestive of subarachnoid hemorrhage
•  Gastrointestinal hemorrhage or urinary tract hemorrhage 
within the past 21 days
•  Arterial puncture at a noncompressible site in past seven days
•  Seizure at onset of stroke
•  Patients taking anticoagulants within 48 hours
•  Elevated partial thromboplastin time or prothrombin time
•  Platelet counts <100,000
•  Patients requiring aggressive treatment to reduce their blood 
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(Box 1). This will limit any attempt to analyze protocol 
violations in this study. This is unfortunate given that protocol 
violations have been noted to be problematic in other studies, 
particularly in community hospital settings [44,45]. Other 
baseline data points that were not recorded (for example, 
patient’s baseline living situation) can also potentially hinder 
future research queries.
In summary, this report describes the process for 
researchers to acquire and decipher the dataset from the 
original NINDS rt-PA trial. A detailed description of the 
dataset has been provided to assist researchers interested in 
further evaluating this pivotal trial and for those researchers 
involved in future trials assessing the role of thrombolytic 
therapy for acute ischemic stroke.  
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